Q1 Earnings Forecast for OCUL Issued By William Blair

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Investment analysts at William Blair issued their Q1 2025 earnings per share estimates for Ocular Therapeutix in a research note issued on Tuesday, April 8th. William Blair analyst L. Hanbury-Brown expects that the biopharmaceutical company will earn ($0.31) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. William Blair also issued estimates for Ocular Therapeutix’s Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.23) EPS and FY2026 earnings at ($1.16) EPS.

Several other brokerages have also recently weighed in on OCUL. Royal Bank of Canada initiated coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price objective on the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, April 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.38.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $7.11 on Friday. Ocular Therapeutix has a fifty-two week low of $4.06 and a fifty-two week high of $11.78. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -5.39 and a beta of 1.49. The company has a 50 day simple moving average of $7.24 and a two-hundred day simple moving average of $8.58. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Donald Notman sold 6,301 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the transaction, the insider now owns 204,563 shares in the company, valued at approximately $1,603,773.92. This trade represents a 2.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers grew its holdings in shares of Ocular Therapeutix by 4.5% during the first quarter. Rhumbline Advisers now owns 223,115 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 9,514 shares during the last quarter. GAMMA Investing LLC grew its stake in Ocular Therapeutix by 6,760.0% during the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 8,112 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Ocular Therapeutix by 1.0% in the fourth quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company’s stock valued at $3,991,000 after purchasing an additional 4,488 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Ocular Therapeutix in the fourth quarter worth about $28,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Ocular Therapeutix by 48.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 218,588 shares of the biopharmaceutical company’s stock worth $1,867,000 after purchasing an additional 70,904 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.